Cargando…

hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers

Pathological evidence of amyloid on nerve biopsy has been the gold standard for diagnosis in hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) for a long time. In this article, we reviewed the pathological findings of a large series of sural nerve biopsies from a cohort of hATTR-PN pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luigetti, Marco, Romozzi, Marina, Bisogni, Giulia, Cardellini, Davide, Cavallaro, Tiziana, Di Paolantonio, Andrea, Fabrizi, Gian Maria, Fenu, Silvia, Gentile, Luca, Grandis, Marina, Marucci, Gianluca, Massucco, Sara, Mazzeo, Anna, Pareyson, Davide, Romano, Angela, Russo, Massimo, Schenone, Angelo, Tagliapietra, Matteo, Tozza, Stefano, Vita, Giuseppe, Sabatelli, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692609/ https://www.ncbi.nlm.nih.gov/pubmed/33114611 http://dx.doi.org/10.3390/brainsci10110780

Ejemplares similares

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy
por: Romozzi, Marina, et al.
Publicado: (2021)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021)

Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects
por: Luigetti, Marco, et al.
Publicado: (2022)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
por: Cortese, Andrea, et al.
Publicado: (2015)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry
por: Bellofatto, Marta, et al.
Publicado: (2022)

Daytime sleepiness and sleep quality in Charcot–Marie–Tooth disease
por: Bellofatto, Marta, et al.
Publicado: (2023)

Correction to: Daytime sleepiness and sleep quality in Charcot–Marie–Tooth disease
por: Bellofatto, Marta, et al.
Publicado: (2023)

Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus
por: Grandis, M., et al.
Publicado: (2020)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

Frequency, entity and determinants of fatigue in Charcot–Marie–Tooth disease
por: Bellofatto, Marta, et al.
Publicado: (2022)

Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis
por: Salvalaggio, Alessandro, et al.
Publicado: (2021)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

RFC1 AAGGG repeat expansion masquerading as Chronic Idiopathic Axonal Polyneuropathy
por: Tagliapietra, Matteo, et al.
Publicado: (2021)

Modified Technique of Ex-PRESS(®) Filtration Device Combined with a Scleral Pocket for Hereditary Transthyretin Amyloidosis (hATTR) Secondary Open-Angle Glaucoma
por: Vieira, Rita, et al.
Publicado: (2023)

Pathological Findings in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Single-Center Experience
por: Luigetti, Marco, et al.
Publicado: (2020)

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis
por: Connolly, Mark P., et al.
Publicado: (2019)

Small Fibre Involvement in Multifocal Motor Neuropathy Explored with Sudoscan: A Single-Centre Experience
por: Luigetti, Marco, et al.
Publicado: (2020)

Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers
por: Salvalaggio, Alessandro, et al.
Publicado: (2020)

A compound score to screen patients with hereditary transthyretin amyloidosis
por: Tozza, Stefano, et al.
Publicado: (2022)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation
por: Tozza, Stefano, et al.
Publicado: (2023)

Quality of life and upper limb disability in Charcot-Marie-Tooth disease: A pilot study
por: Mori, Laura, et al.
Publicado: (2022)

Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
por: Gentile, Luca, et al.
Publicado: (2021)

Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
por: Pareyson, Davide, et al.
Publicado: (2011)

Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience
por: Ferraro, Pietro Manuel, et al.
Publicado: (2021)

Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017
por: Prada, Valeria, et al.
Publicado: (2019)

Nerve Biopsy in Peripheral Neuropathies: Not All Water Is under the Bridge
por: Luigetti, Marco, et al.
Publicado: (2021)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Imaging cardiac ATTR amyloid
por: Hawkins, Philip N
Publicado: (2015)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tl06sl71pd7dkk65ed28650k7k